Nkarta, Inc. (NKTX)
Largest Insider Buys in Sector
NKTX Stock Price History Chart
NKTX Stock Performance
About Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic …
Insider Activity of Nkarta, Inc.
Over the last 12 months, insiders at Nkarta, Inc. have bought $50M and sold $419,335 worth of Nkarta, Inc. stock.
On average, over the past 5 years, insiders at Nkarta, Inc. have bought $149.67M and sold $1.61M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $900M. George Simeon (director) — $60M.
The last purchase of 3,000,000 shares for transaction amount of $30M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.
List of Insider Buy and Sell Transactions, Nkarta, Inc.
| 2024-07-16 | Sale | Chief Legal Officer | 3,396 0.0065% | $8.00 | $27,168 | -47.31% | ||
| 2024-06-18 | Sale | Chief Executive Officer | 1,770 0.0022% | $5.60 | $9,912 | -15.94% | ||
| 2024-06-18 | Sale | Chief Scientific Officer | 456 0.0006% | $5.60 | $2,554 | -15.94% | ||
| 2024-06-18 | Sale | Chief Medical Officer | 456 0.0006% | $5.60 | $2,554 | -15.94% | ||
| 2024-06-18 | Sale | Chief Legal Officer | 727 0.0009% | $5.60 | $4,071 | -15.94% | ||
| 2024-06-18 | Sale | Chief Technical Officer | 229 0.0003% | $5.60 | $1,282 | -15.94% | ||
| 2024-03-27 | 3M 5.4767% | $10.00 | $30M | -49.57% | ||||
| 2024-03-27 | director | 2M 3.6511% | $10.00 | $20M | -49.57% | |||
| 2024-03-01 | Sale | Chief Technical Officer | 8,367 0.0167% | $12.51 | $104,671 | -53.50% | ||
| 2024-02-12 | Sale | Chief Scientific Officer | 4,143 0.0088% | $12.00 | $49,716 | -44.21% | ||
| 2024-01-16 | Sale | Chief Executive Officer | 9,697 0.02% | $8.74 | $84,752 | -24.73% | ||
| 2024-01-16 | Sale | Chief Scientific Officer | 4,560 0.0094% | $8.74 | $39,854 | -24.73% | ||
| 2024-01-16 | Sale | Chief Medical Officer | 3,552 0.0073% | $8.74 | $31,044 | -24.73% | ||
| 2024-01-16 | Sale | Chief Legal Officer | 4,554 0.0094% | $8.74 | $39,802 | -24.73% | ||
| 2024-01-16 | Sale | Chief Technical Officer | 2,512 0.0052% | $8.74 | $21,955 | -24.73% | ||
| 2023-08-21 | Sale | Chief Medical Officer | 1,331 0.0027% | $1.83 | $2,436 | +246.70% | ||
| 2023-06-20 | Sale | Chief Executive Officer | 1,704 0.0035% | $4.85 | $8,264 | -6.16% | ||
| 2023-06-20 | Sale | Chief Scientific Officer | 439 0.0009% | $4.85 | $2,129 | -6.16% | ||
| 2023-06-20 | Sale | See Remarks | 526 0.0011% | $4.85 | $2,551 | -6.16% | ||
| 2023-06-20 | Sale | Chief Medical Officer | 439 0.0009% | $4.85 | $2,129 | -6.16% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 10050818 14.2426% | $2.37 | 3 | 0 | <0.0001% | |
| George Simeon | director | 1548341 2.1941% | $2.37 | 2 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 3150732 4.4648% | $2.37 | 1 | 0 | <0.0001% | |
| MAKOWER JOSHUA | 10 percent owner | 2902115 4.1125% | $2.37 | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 2902115 4.1125% | $2.37 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $116.8M | 15.33 | 10.81M | +38.44% | +$32.43M | 0.12 | |
| Boxer Capital, LLC | $60.62M | 7.96 | 5.61M | +289.4% | +$45.05M | 1.24 | |
| Deerfield Management | $56.15M | 7.37 | 5.19M | +52.77% | +$19.39M | 0.14 | |
| Adage Capital Partners Gp L L C | $41.08M | 5.39 | 3.8M | +10.14% | +$3.78M | 0.08 | |
| Samsara Biocapital Llc | $40.73M | 5.35 | 3.77M | +31.38% | +$9.73M | 6.35 |